Skip to main content

deramiocel

Generic: allogeneic cardiosphere-derived cells (CDCs)

deramiocel: developed by 1 company · 2 clinical trials tracked.

deramiocel evidence translation

What we can confirm

What it means

Source-backed records connect deramiocel to CAPR; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could deramiocel → CAPR affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
CAPRICOR THERAPEUTICS, INC. (CAPR)
Muscular Dystrophies; Duchenne Muscular Dystrophy
Phase 2
Clinical Trials (2)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

NCT05126758·Phase 3·CAPR
Active, not recruiting

Primary endpoint: Change in the upper limb function

InterventionalRandomizedquadruple106 enrolledStarted 2022-06Completion 2027-0320 sites · United StatesCapricor Inc.

Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial

NCT04428476·Phase 2·CAPR
Active, not recruiting

Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Month 12

Interventionalopen13 enrolledStarted 2020-08Completion 2026-055 sites · United StatesCapricor Inc.

Frequently asked questions

Who is developing deramiocel?

deramiocel is being developed by CAPRICOR THERAPEUTICS, INC..

How many clinical trials involve deramiocel?

BioSniper tracks 2 clinical trials involving deramiocel.